Medicaid_Journavx_20250514
Defines clinical eligibility, quantity limits, coverage duration, step therapy coding logic, and exclusion for investigational use for Journavx (suzetrigine) for Neighborhood Health Plan of Rhode Island Medicaid members.
No material clinical/coverage changes.
Coverage Summary
Coverage stance: covered_with_criteria for Journavx (suzetrigine) for Neighborhood Medicaid members. Scope: defines clinical eligibility (including age >=18, documentation of moderate to severe pain, prior trial and failure of at least one generic pain medication within the previous 30 days or documentation that alternatives are inappropriate, or history of opioid use disorder), quantity limits (Journavx 50 mg — 29 tablets per 14-day supply every 6 weeks), coverage duration (6 weeks), and step therapy coding logic (coverage may be allowed if there is at least one paid claim for a buprenorphine product for opioid dependence). Investigational uses or doses/conditions not recognized as medically accepted indications are not covered.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.